Liminatus Pharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 |
|---|---|---|
| Operating income | -$3.0M | -$3.3M |
| Operating expenses | $3.0M | $3.3M |
| Cash from operations | -$10.0M | -$1.5M |
| Capital expenditure | $13,108 | — |
| Free cash flow | -$10.0M | — |
| Total assets | $512,795 | $5.4M |
| Total liabilities | $10.3M | $24.7M |
Shares outstanding 44.9M · Free float 62.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.